Medicine details
| Image |  |
| Name | Dapazin |
| Dosage | Tablet |
| Generic Name | Dapagliflozin |
| Classes |
Antidiabetic Agent Metabolic Agent |
| Diseases | |
| Company | Concord Pharmaceuticals Ltd. |
Drug Package Details
| Strength | 5 mg |
| Storage Condition | |
| Origin Country | Bangladesh |
| Commercial Pack | 28 |
| Price per pack | ৳ 840.00 |
| Cost per pack | ৳ 739.20 |
| Package unit | 8 tabs strip |
| Price per unit | ৳ 30.00 |
| Cost per unit | ৳ 26.40 |
| Discount | 0 |
| Coupon | |
| Remarks |
Dapagliflozin
Dapagliflozin is an antidiabetic drug from the class SGLT-2 inhibitors. Dapagliflozin inhibits sodium-glucose like transporter 2, a transport protein that reabsorbs sodium & glucose from urine into the blood. As a result, glucose is excreted in urine and blood glucose level drops.
Type 2 Diabetes Mellitus
- To improve glycemic control the recommended starting dose is 5 mg once daily, taken in the morning. Increase dose to 10 mg once daily in patients tolerating 5 mg who require additional glycemic control.
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors, the recommended dose is 10 mg once daily.
- Dapagliflozin is not recommended for glycemic control when the eGFR is less than 45 mL/min/1.73 m2.
Heart Failure
The recommended dose of Dapagliflozin is 10 mg once daily.
Commonly associated side effects are-
- Vaginal candidiasis
- Urinary tract infections
- pharyngitis
- Volume depletion: Before initiating Dapagliflozin, assess volume status and renal function in the elderly, patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy.
- Ketoacidosis in Patients with Diabetes Mellitus: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis regardless of blood glucose level. If suspected, discontinue Dapagliflozin, evaluate and treat promptly. Before initiating Dapagliflozin, consider risk factors for ketoacidosis. Patients on Dapagliflozin may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis.
- Urosepsis and Pyelonephritis: Evaluate for signs and symptoms of urinary tract infections and treat promptly, if indicated.
- Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with Dapagliflozin.
- Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious, life-threatening cases have occurred in patients with diabetes, both females and males. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment.
- Genital Mycotic Infections: Monitor and treat if indicated.
Contraindication
Contraindicated in patients hypersensitive to any component of the medication.
None known.
Contraindicated in-
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Patients on dialysis
Bangla
English